(Q35744418)

10 August 2017

1 reference

title

Single-isomer drugs: true therapeutic advances (English)

1 reference

10 August 2017

1 reference

ChEBI release 2020-05-28

Tommy Andersson

1

1 reference

10 August 2017

1 January 2004

1 reference

Clinical Pharmacokinetics

10 August 2017

1 reference

10 August 2017

43

1 reference

10 August 2017

5

1 reference

10 August 2017

279-285

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200443050-00001

10 August 2017

0 references

cites work

A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial

1 reference

12 December 2020

Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group

1 reference

12 December 2020

Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism

1 reference

12 December 2020

Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole

1 reference

12 December 2020

Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group

1 reference

12 December 2020

Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial

1 reference

12 December 2020

Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole.

1 reference

12 December 2020

Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial

1 reference

12 December 2020

Appropriate acid suppression for the management of gastro-oesophageal reflux disease

1 reference

12 December 2020

Opposing time trends of peptic ulcer and reflux disease

1 reference

12 December 2020

Putting chirality to work: the strategy of chiral switches

1 reference

12 December 2020

Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole

1 reference

12 December 2020

Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: The U.S. multicenter study

1 reference

12 December 2020

Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole

1 reference

12 December 2020

Comparison of once-daily doses of omeprazole (40 and 20 mg) and placebo in the treatment of benign gastric ulcer: a multicenter, randomized, double-blind study

1 reference

12 December 2020

Comparative tolerability profile of omeprazole in clinical trials

1 reference

12 December 2020

Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial

1 reference

12 December 2020

Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man

1 reference

12 December 2020

[Chiral switch, a successful way for developing drugs: example of esomeprazole]

1 reference

12 December 2020

Omeprazole: the first proton pump inhibitor

1 reference

12 December 2020

Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes

1 reference

12 December 2020

Epidemiology and natural history of gastro-oesophageal reflux disease

1 reference

12 December 2020

The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH.

1 reference

12 December 2020

[Suppression of acid secretion and plasma level of a once-daily dose of omeprazole]

1 reference

12 December 2020

10.2165/00003088-200443050-00001

Identifiers

DOI

1 reference

PubMed ID

15080761

Dimensions Publication ID

10 August 2017

0 references

1 reference

PubMed ID

15080761